Enceph-IG
Research type
Research Study
Full title
Intravenous Immunoglobulin in Autoimmune Encephalitis in Adults – A Randomised Double-Blind Placebo-Controlled Trial
IRAS ID
280904
Contact name
Tom Solomon
Contact email
Sponsor organisation
University of Liverpool
Eudract number
2020-004428-40
ISRCTN Number
ISRCTN69615004
Duration of Study in the UK
6 years, 0 months, 30 days
Research summary
Some doctors think that if IVIG is used from the start of treatment, patients may recover more quickly and have less side effects from the illness. While IVIG may help patients it can have side effects, including blood clots or allergic reactions, is expensive and may not help recovery. Currently it is used in about 50% of patients with autoimmune encephalitis. The ENCEPH-IG trial (Intravenous immunoglobulin in autoimmune encephalitis in adults) is a study looking at whether or not early treatment with IVIG improves recovery. ENCEPH-IG is an individually randomised controlled trial of 356 adults: half will receive IVIG, and the other half will receive a placebo. The study will be carried out at approximately 50 hospitals in the Brain Infections UK network.
REC name
Wales REC 3
REC reference
21/WA/0050
Date of REC Opinion
25 Mar 2021
REC opinion
Further Information Favourable Opinion